Research programme: protein phosphatase magnesium-dependent 1 inhibitors - Antisoma/The Institute of Cancer Research

Drug Profile

Research programme: protein phosphatase magnesium-dependent 1 inhibitors - Antisoma/The Institute of Cancer Research

Alternative Names: PPM1D inhibitors - Antisoma

Latest Information Update: 15 Jun 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Antisoma; The Institute of Cancer Research
  • Class
  • Mechanism of Action Protein phosphatase 2C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 20 May 2010 Antisoma is looking for a licensing partnership for the programme
  • 07 Oct 2008 Preclinical trials in Cancer in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top